BioInvent Treats First Patient In Phase I Study Of BI-505

BioInvent International (BioInvent) has treated first patient in an open, dose-escalation Phase I study of antibody BI-505 for patients with advanced multiple myeloma. The Phase I study will investigate safety, pharmacokinetics and pharmacodynamics, and will aim to define the optimal dose of the antibody for upcoming clinical Phase II development.

The company said that the study will involve 30 – 40 patients. In the study, the patients will be treated with intravenous doses of BI-505 every other week for a 28-day period with the possibility of extending the treatment until the condition deteriorates again. The study will be conducted at clinics in the US and will be overseen by renowned multiple myeloma experts.

The company claimed that BI-505 is a human antibody derived from BioInvent’s proprietary n-CoDeR library based on its ability to bind to a tumour-associated receptor (the adhesion molecule ICAM-1) and induce programmed cell death (apoptosis) in tumour cells.

Svein Mathisen, CEO of BioInvent, said: “We are delighted that the clinical studies of BI-505 have started. We believe that BI-505 can address a major unmet medical need and be an important treatment alternative for multiple myeloma.”